化療引起的中性粒細胞減少症治療市場- 按治療類型（G-CSF、抗生素、粒細胞輸注、抗真菌藥）、藥物類型（品牌、生物學名藥）、給藥途徑（腸胃外、口服）、配銷通路與預測，2024 - 2032 年

由於批准生物相似藥的有利監管途徑以及處方者和患者的接受度不斷提高，全球化療引起的中性粒細胞減少症治療市場規模在 2024 年至 2032 年期間複合年成長率將達到 3.7%。

包括癌症在內的慢性疾病的盛行率是市場的主要成長因素。根據CDC報告，在美國，每年有170萬人被診斷出罹患癌症，導致超過60萬人死亡，成為第二大死因。癌症治療費用不斷增加，預計到 2030 年將超過 2,400 億美元。對 CIN 合理管理的需求不斷成長，凸顯了生物相似藥等創新治療方案的可行性。透過為傳統治療提供具有成本效益的替代方案，生物相似藥滿足了對可獲取且具有成本效益的中性粒細胞減少症治療日益成長的需求，從而推動了市場成長。

化療引起的中性粒細胞減少症治療行業根據治療類型、藥物類型、給藥途徑、配銷通路和地區進行分類。

到 2032 年，生物相似藥領域將快速成長，因為它們提供了傳統療法的經濟高效的替代方案。用於治療中性粒細胞減少症的生物相似藥的可用性不斷增加，使醫療保健提供者有機會最佳化治療方案，同時降低醫療保健成本。此外，由於全球醫療保健基礎設施面臨越來越大的壓力，需要在不影響患者護理的情況下控制成本，生物相似藥的引入是一種有吸引力的解決方案，可以減輕財務負擔，同時保持安全標準，這將推動該領域的成長。

由於便利性和靈活性，口服製劑細分市場將在 2024 年至 2032 年期間適度成長。治療中性粒細胞減少症的口服溶液的開發使得以患者為中心的治療成為可能，這樣人們就可以在門診甚至在舒適的家中接受治療。此外，藥物傳遞技術的創新提高了口服製劑的生物利用度和藥物動力學，進一步增加了其使用。

由於強大的醫療基礎設施和高癌症發病率，歐洲化療引起的中性粒細胞減少症治療行業規模將在 2024 年至 2032 年間強勁成長。在腫瘤學投資和先進治療方法的採用的推動下，德國、英國和法國等國家正在引領產業成長。此外，製藥公司和研究機構之間的合作使得中性粒細胞減少症新療法的開發和商業化成為可能。該地區積極主動的癌症治療方法和有利的政策有助於其在全球市場中的顯著地位。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 癌症盛行率增加
    • 越來越多採用化療
    • 治療方案的技術進步
    • 政府措施和資金不斷增加
  • 產業陷阱與挑戰
    • 治療費用高
    • 治療的不良反應
• 成長潛力分析
• 監管環境
• 管道分析
• 波特的分析
• PESTEL分析
• 未來市場趨勢

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按治療類型，2021 - 2032 年

• 主要趨勢
• 粒細胞集落刺激因子治療
• 抗生素
• 粒細胞輸注
• 抗黴菌藥
• 其他治療類型

第 6 章：市場估計與預測：按藥物類型，2021 - 2032 年

• 主要趨勢
• 品牌化
• 生物相似藥

第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年

• 主要趨勢
• 注射用
• 口服

第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 網路藥局

第 9 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 10 章：公司簡介

• Amgen Inc.
• BeyondSpring Inc.
• Biocon Biologics Inc.
• Cellerant Therapeutics
• Coherus BioSciences, Inc.
• Evive Biotech
• Kyowa Kirin Co., Ltd.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Spectrum Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.

The global chemotherapy-induced neutropenia treatment market size will register 3.7% CAGR during 2024-2032, owing to favorable regulatory pathways for approval of biosimilars and growing acceptance among prescribers and patients.

Prevalence of chronic diseases including cancer is a major growth factor for the market. According to the CDC report, in the US, 1.7 million people are diagnosed with cancer annually, with over 600,000 fatalities, making it the second leading cause of death. The cost of cancer care is continually increasing and is projected to exceed $240 billion by 2030. As the cases of cancer surge worldwide, so does the use of chemotherapy as a treatment modality, increasing the likelihood of chemotherapy-induced neutropenia (CIN). This growing demand for rational management of CIN highlights the viability of innovative treatment options such as biosimilars. By providing cost-effective alternatives to conventional treatments, biosimilars address the growing need for accessible and cost-effective neutropenia treatments, which is driving market growth.

Chemotherapy-induced neutropenia treatment industry is classified based on treatment type, drug type, route of administration, distribution channel, and region.

The biosimilars segment will grow rapidly through 2032, as they offer cost-effective alternative to conventional therapies. The increasing availability of biosimilars for the treatment of neutropenia has given healthcare providers the opportunity to optimize treatment regimens while reducing healthcare costs. Additionally, as healthcare infrastructure worldwide is under increased pressure to contain costs without compromising patient care, the introduction of biosimilars is an attractive solution to lighten the financial burden while maintaining safety standards, which will drive growth in the segment.

The oral formulations segment will grow moderately during 2024-2032, due to the convenience and flexibility. The development of oral solutions to treat neutropenia enable patient-centered treatments so that people can receive treatment on an outpatient basis or even in the comfort of their own home. In addition, innovations in drug delivery techniques have increased the bioavailability and pharmacokinetics of oral formulations, further increasing their use.

Europe chemotherapy-induced neutropenia treatment industry size will grow strongly between 2024 and 2032, due to robust healthcare infrastructure and high incidence of cancer. Countries such as Germany, the United Kingdom and France are leading industry growth, fueled by investments in oncology and the adoption of advanced treatments. In addition, collaboration between pharmaceutical companies and research institutes enables the development & commercialization of new treatments for neutropenia. The region's proactive approach to cancer treatment and favorable policies contribute to its notable position in the global market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cancer
    • 3.2.1.2 Growing adoption of chemotherapy
    • 3.2.1.3 Technological advancements in treatment options
    • 3.2.1.4 Rising government initiatives and funding
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Adverse effects of treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis
• 3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Granulocyte colony-stimulating factor therapy
• 5.3 Antibiotics
• 5.4 Granulocyte transfusion
• 5.5 Antifungals
• 5.6 Other treatment types

Chapter 6 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Branded
• 6.3 Biosimilars

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Parenteral
• 7.3 Oral

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Amgen Inc.
• 10.2 BeyondSpring Inc.
• 10.3 Biocon Biologics Inc.
• 10.4 Cellerant Therapeutics
• 10.5 Coherus BioSciences, Inc.
• 10.6 Evive Biotech
• 10.7 Kyowa Kirin Co., Ltd.
• 10.8 Novartis AG
• 10.9 Pfizer Inc.
• 10.10 Sanofi
• 10.11 Spectrum Pharmaceuticals
• 10.12 Teva Pharmaceutical Industries Ltd.